Farmas USA

Por FB y su +4% en AH?

De nuestro sector, vaya velas mas flojas en muchas y feuchas en otras ...

sobre AMRN

Jefferies-Potential Beat On Growing Q1 Vascepa Sales - Debate on Expectations $30 target Price
AMRN could report Q1 EPS results in the first week of May and we note IMS scripts have reached all-time highs over the past 9 of 10 weeks, tracking to perhaps ~$75-80M and possibly well above consensus $67M (4 ests). 2019 guidance of $350M would then look conservative and too low. For 2019, we are above at $385M and above cons $365M and guidance could eventually move higher towards our estimate.

Insights

Weekly scripts appear to reach record highs, setting up AMRN for a pot'l Q1 sales beat

Despite management cautioning to expect seasonality in Q1, scripts are up +16% Q/Q (accelerated even more than the +13-15% in Q4) - appearing to track to ~$75-80M in Q1 vs cons $67M (4 ests) and Jefferies at $79M. Historically, Vascepa sales have declined in Q1 over the past couple of years, but we see an increase this year instead due to 1) major new CVOT data during Q4 now published in the NEJM, 2) huge salesforce increase to 400 from 150 recently, and 3) positive doc channel checks suggesting reimbursement has not been much issue. We also note Q4 reported sales were even higher than third-party data (+40% vs +13%) suggesting Q1 IMS script data could be inaccurate (under-capturing) as well although management recently confirmed weekly scripts are tracking fairly accurately to AMRN's internal datapoints. Bigger picture, 2019 guidance of $350M appears conservative and only suggests an $80M+$85M+$90M+$95M trajectory (i.e. modest growth), even though sales grew by a whopping $20M+ Q/Q to $77M in Q4.

Additional Q1 dynamics and thoughts

We acknowledge some buysiders think a beat is already expected given third-party data is available though we argue confirming these strong results after last quarters doubt (huge beat in Q4) would be positive and it means consensus is going up. We also understand the stock has been in a trading range from teens to low $20s and investors seem to want to debate "M&A takeout or bust" more than anything with bears saying no takeout until litigation is settled and FDA label expansion confirmed.

Our estimated $79M in Q1 considers 1) a +9% price increase Dec 2018, 2) offset by increased gross to net typical of Q1, and 3) higher capture of 75% vs 72% for Q4 to be conservative. We can derive Q1 sales of ~$80M were we to assume a G2N of 55% (vs 50% for other quarters). Alternatively, adjusting the capture to historical of 83% (our est) would yield Q sales closer to the $70-75M range, which would still be above consensus estimates of $67M.

Our doctors consistently provide positive feedback on Vascepa

Anecdotally, docs inform us they have "accelerated their prescriptions" post the Nov 2018 AHA conference. The LDL increase in the placebo arm (mineral oil) has not deterred docs from prescribing Vascepa. From our NYC Doc Panel day last month, post the data, one doc increased his prescriptions by 3x-4x to 10/month, while the other doctor now prescribes it several times a month. The latter was formerly not a strong believer in triglyceride (TG) therapies unless patients exceeded the >500mg/dL threshold, but he now envisions his overall usage for "elevated" TG patients to increase as he becomes more familiar and comfortable and reimbursement has been easy

Con la ausencia de fortaleza que muestra el sector poco se puede hacer.

SP, en efecto, no ha podido. Lo normal es no hacerlo a la primera.

Nasdaq 100 que es el que más fortaleza ha mostrado, es el que menos me gusta cómo ha cerrado, se puede intuir que hay ventas en mayor medida que otros índices.

Esas TEVA ...

el breakout esta ahí, hoy se apoyo en la bajista superada … de momento todo en orden ...

EXEL

Exelixis’ Partner Takeda Announces Filing of New Drug Application in Japan for CABOMETYX® (Cabozantinib) for Advanced Renal Cell Carcinoma

-- Regulatory submission triggers $10 million milestone payment toExelixis under collaboration and license agreement with Takeda --

-- Submission based on METEOR and CABOSUN trials as well as Takeda bridging study --

http://ir.exelixis.com/news-releases/news-release-details/exelixis-partner-takeda-announces-filing-new-drug-application

Exelixis (EXEL) Receives a Buy from Oppenheimer

https://www.analystratings.com/articles/exelixis-exel-receives-a-buy-from-oppenheimer/

https://www.elperiodico.com/es/sanidad/20190425/curado-un-nino-con-leucemia-mediante-la-primera-terapia-car-t-publica-7423689?fbclid=IwAR0aXK3yUC2WUMHPfOtU07bgPOtGVm14NCxvEdEpJxuK9MEYIimTVyKX9r0
CAR-T novartis junto gilead, me alegro por el peque!

ACAD

Inició fase III a y próxima b esperadas con primavaserin para trastornos por depresión

http://www.streetinsider.com/Corporate+News/Acadia+Pharma+%28ACAD%29+Commences+Phase+3+CLARITY+Program+with+Pimavanserin+as+Adjunctive+Treatment+for+Major+Depressive+Disorder/15406036.html?si_client=intbro